Advertisement

Topics

FDA Grants Orphan Drug Designation to Acceleron’s Facioscapulohumeral Muscular Dystrophy Drug

16:33 EDT 12 Jul 2018 | Speciality Pharma Journal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Company’s locally acting “Myostatin+” muscle agent, for the treatment of patients with …

Original Article: FDA Grants Orphan Drug Designation to Acceleron’s Facioscapulohumeral Muscular Dystrophy Drug

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation to Acceleron’s Facioscapulohumeral Muscular Dystrophy Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...